News

July 10, 2017July 10, 2017

Cancer Research Institute Announces $1 Million Technology Impact Award Winner

Dongeun Huh, PhD, from the University of Pennsylvania’s Department of Bioengineering, is the recipient of the Cancer Research Institute’s (CRI) inaugural Technology Impact Award to advance the field of immuno-oncology. Huh will receive ... Read more

July 7, 2017July 7, 2017

Opdivo Keeps Melanoma from Recurring Longer Than Yervoy, Phase 3 Clinical Trial Shows

News

It took longer for advanced melanoma to recur in patients treated with Bristol-Myers Squibb’s Opdivo (nivolumab) than in patients who received Yervoy, according to a Phase 3 clinical trial. The ... Read more

July 6, 2017July 6, 2017

CRI’s 2017 Immunotherapy Patient Series Launches July 8 in San Francisco

News

Registration is now open for the 2017 Immunotherapy Patient Summit Series, a set of free half-day events in five U.S. cities focusing on immunotherapy and clinical trials, says the Cancer Research Institute ... Read more

July 5, 2017

EFFECTOR to Work with Pfizer and Merck on Evaluating Colorectal Cancer Immunotherapy Combo

News

EFFECTOR Therapeutics will team up with Pfizer and Merck’s operation in Darmstadt, Germany, to evaluate an immuno-oncology combination theapy in patients with microsatellite stable colorectal cancer. Set to begin in the third quarter of ... Read more

June 30, 2017June 30, 2017

‘Follow that Cell Challenge’ Winners Receive $400,000 for New Tools to Predict Cell Behavior

News

Biological engineers Nader Pourmand, PhD, of the University of California Santa Cruz, and Paul Blainey, PhD, of the Broad Institute at Cambridge, Massachusetts, are the first- and second-place winners, ... Read more

June 29, 2017June 29, 2017

Blood Protein Levels May Predict Cervical Cancer Patients Likely to Benefit from Advaxis’ Immunotherapy

News

Measuring the blood levels of certain proteins before treatment may help identify patients more likely to benefit from Advaxis‘ immunotherapy vaccine candidate axalimogene filolisbac (axal). In the GOG/NRG-0265 Phase 2 ... Read more

June 28, 2017July 1, 2017

Clinical Trial Evaluating Combination of Cabometyx, Tecentriq in Advanced Cancer Starting

News

A Phase 1 trial assessing the combination of Exelixis‘ Cabometyx (cabozantinib) and Genentech‘s Tecentriq (atezolizumab) in locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC) is set to ... Read more

June 27, 2017June 27, 2017

83% of Young Leukemia Patients Treated with CTL019 Achieve Remission, and It Lasts, Update Shows

News

The leukemia of 83 percent of young patients treated with Novartis’ CTL019 was in remission three months after the therapy administered, and it lasted six months, researchers reported. There were ... Read more

June 26, 2017June 27, 2017

Cash-strapped ImmunoCellular Reviews ICT-107 Status, Suspends Phase 3 Trial for Glioblastoma

News

ImmunoCellular Therapeutics has suspended further patient randomization in its Phase 3 trial for its ICT-107, after determining that it cannot secure enough funding to complete the trial (NCT02546102). The study was ... Read more

June 23, 2017July 4, 2017

Ilixadencel Provokes Strong Response Against Kidney Cancer, Phase 1/2 Clinical Trial Shows

News

Injecting ilixadencel into the tumors of newly diagnosed metastatic kidney cancer patients provoked a potent immune response to the disease, according to the first stage of a Phase 1/2 ... Read more